Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score on Rankin scale · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with prednisolone (moderate certainty).
1 finding from 1 review
Change in neuropathy symptoms · people with DPN
1 finding from 1 review
Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with DPN
1 finding from 1 review
Change in any validated quality of life score · people with DPN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications of DPN · people with DPN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with DPN
Alpha‐lipoic acid showed no clear difference in adverse events leading to cessation of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Reduction in pain intensity · Morton's neuroma
1 finding from 1 review
Adverse events · Morton's neuroma
Summary of findings: ultrasound‐guided injection of corticosteroid… showed no clear difference in adverse events compared with non‐ultrasound‐guided injection of corticosteroid and local… (low certainty).
1 finding from 1 review
Pain at short term (4 weeks) VAS 10‐cm scale, which was translated to a 0 to 100 scale in which lower scores mean less pain. · Morton's neuroma
The review found no eligible studies for this question.
1 finding from 1 review
Function: restrictions in daily activities (4‐item Likert scale) · Morton's neuroma
The review found no eligible studies for this question.
1 finding from 1 review
Health‐related quality of life · Morton's neuroma
The review found no eligible studies for this question.
1 finding from 1 review